Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?

Authors:
Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT and 1 more

Journal:
AAPS J

Publication Year: 2018

DOI:
10.1208/s12248-018-0257-y

PMCID:
PMC8364290

PMID:
30187153

View on PubMed View on PMC View Publisher
Journal Information

Full Title: AAPS J

Abbreviation: AAPS J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
Gorovits B; Azadeh M; Buchlis G and 12 more (2023) - Transparency Score: 3/6
Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles.
Kim H; Kirtane AR; Kim NY and 6 more (2023) - Transparency Score: 3/6
Lessons from CDER's Quality Management Maturity Pilot Programs.
Maguire J; Fisher A; Harouaka D and 9 more (2023) - Transparency Score: 2/6
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepat…
Purohit V; Huh Y; Wojciechowski J and 5 more (2023) - Transparency Score: 4/6
Benchmarking the Quality Practices of Global Pharmaceutical Manufacturing to Advance Supply Chain R…
Fellows M; Friedli T; Li Y and 8 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest AS Strik has received lecture fees from Merck Sharp & Dohme, Takeda, AbbVie, Mundipharma, Pfizer, Janssen-Cilag, and Tillots. DR Mould is the founder and president of Projections Research Inc., a consulting company that conducts population PK and PKPD evaluations for the pharmaceutical industry. Laura Ruff, William Yashar, and Bradley Messmer are all employed by Abreos Biosciences Inc., a company that produces point-of-care assays. While Y-MC Wang is an employee of the Food and Drug Administration (FDA), the scientific perspectives expressed herein do not represent the policy of the FDA."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025